Immunogenicity and Efficacy of TNX-1800, A Live Virus Recombinant Poxvirus Vaccine Candidate, against SARS-CoV-2 Challenge in Nonhuman Primates

TNX-1800 is a synthetically derived live recombinant chimeric horsepox virus (rcHPXV) vaccine candidate expressing Wuhan SARS-CoV-2 spike (S) protein. The primary objective of this study was to evaluate the immunogenicity and efficacy of TNX-1800 in two nonhuman primate species challenged with USA-W...

Descripción completa

Detalles Bibliográficos
Autores principales: Awasthi, Mayanka, Macaluso, Anthony, Myscofski, Dawn, Prigge, Jon, Koide, Fusataka, Noyce, Ryan S., Fogarty, Siobhan, Stillwell, Helen, Goebel, Scott J., Daugherty, Bruce, Nasar, Farooq, Bavari, Sina, Lederman, Seth
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674175/
https://www.ncbi.nlm.nih.gov/pubmed/38006014
http://dx.doi.org/10.3390/vaccines11111682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10674175/
https://www.ncbi.nlm.nih.gov/pubmed/38006014
http://dx.doi.org/10.3390/vaccines11111682

Ejemplares similares